Live updates

First case of Ebola diagnosed in the US

The US Centers for Disease Control and Prevention has confirmed the first case of Ebola diagnosed in the US.

Texas Health Presbyterian Hospital of Dallas officials said in a statement yesterday that an unnamed patient was being tested for Ebola and had been placed in "strict isolation" due to the patient's symptoms and recent travel history.


Leicester has 'highest number of tots with tooth decay'

Leicester has the highest number of three-year-olds with tooth decay, according to a health report.

Public Health England (PHE) identified four regions where young children were most likely to have rotting teeth:

  • The East Midlands
  • North West
  • London
  • Yorkshire and the Humber
  • The lowest was South Gloucestershire where just 2% of children suffered from the problem.

One in every eight children 'suffering from tooth decay'

One in every eight tots in England suffers from tooth decay because they are eating too much sugar, health officials have warned.

Children are damaging their teeth with too many sugary foods, PHE warned. Credit: PA

Public Health England (PHE) found 12% of three-year-olds in England were damaging their teeth because their parents were frequently giving them sugary foods and drinks.

There was a stark variation in dental health across the country - a third of three-year-olds had rotting teeth in some parts of England, according to PHE's first national survey of the oral health of young children.

However, in some parts only 2% of children suffered from tooth decay.

Experts examined the teeth of more than 50,000 youngsters at their nursery, children's centre or playgroup during 2012/13


Breast cancer drug 'could extend life by five years'

Credit: Rui Vieira/PA Archive

A new breast cancer drug could extend the lives of patients with an advanced form of the disease by almost five years, a study has found.

Women with an aggressive type of cancer could benefit from using perjeta as a combination with chemotherapy and the drug herceptin, researchers said.

Trials into the effectiveness of the combination treatment found survival rates among women with previously untreated advanced HER2-positive breast cancer was extended by more than four and a half years.

UK study lead Professor David Miles, consultant oncologist at Mount Vernon Cancer Centre in London, said: "These results are impressive.

"They show a magnitude of survival benefit which we have never seen before in advanced breast cancer, let alone this particular type, previously regarded as having a poor prognosis and being difficult to treat."

Perjeta, manufactured by drug company Roche, is a targeted treatment which works to block cancer cell growth and cell signalling.

It is not currently available on the NHS but a final recommendation is yet to be issued.

Read more: 700,000 UK women at risk of 'hidden' breast cancer

'More must be done' to identify higher breast density

Doctors need to do more to identify women with higher breast density early in the battle against breast cancer, a leading health expert has said.

Baroness Delyth Morgan, chief executive at Breast Cancer Campaign, said the mots effective way to stop the disease was to prevent from occurring in the first place.

The best weapon in overcoming breast cancer is the ability to stop the disease occurring in the first place. To do this, we need better ways to identify who is most at risk.

The emerging evidence on risk factors such as breast density, which we now know is putting hundreds of thousands of women at risk of developing breast cancer, must be taken into consideration and more must be done.

– Baroness Delyth Morgan
Load more updates